scholarly journals Long‐term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS‐PTS study

2020 ◽  
Vol 18 (4) ◽  
pp. 857-864 ◽  
Author(s):  
Jean‐Philippe Galanaud ◽  
Marc Righini ◽  
Lorris Le Collen ◽  
Aymeric Douillard ◽  
Helia Robert‐Ebadi ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Postthrombotic Syndrome ◽  
Vein Thrombosis ◽  
Distal Deep Vein Thrombosis ◽  
Deep Vein

Catheter-based treatment of ilio-femoral deep vein thrombosis - an update on current evidence

VASA ◽  
2013 ◽  
Vol 42 (3) ◽  
pp. 161-167 ◽  
Author(s):  
Jennifer Fahrni ◽  
Rolf P. Engelberger ◽  
Nils Kucher ◽  
Torsten Willenberg ◽  
Iris Baumgartner
Keyword(s):  
Deep Vein Thrombosis ◽  
High Rate ◽  
Current Evidence ◽  
Bleeding Complications ◽  
Postthrombotic Syndrome ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Vein Thrombosis ◽  
Deep Vein

Ilio-femoral deep vein thrombosis (DVT) has a high rate of long-term morbidity in the form of the postthrombotic syndrome (PTS). Therefore, management of acute thrombosis should not only focus on the prevention of acute complications such as propagation or embolisation of the initial clot but also on preventing PTS and recurrent thrombosis. Contemporary catheter-based treatments of deep vein thrombosis have proven to be safe and effective in selected patients. Current guidelines recommend medical therapy with anticoagulation alone for all but the most severe, limb-threatening thrombosis. They additionally allow for consideration of catheter-based treatment in patients with acute DVT and low risk of bleeding complications to prevent PTS. Recent studies favoring interventional therapy have not been included in these guidelines. Data on long-term outcome is expected to be published soon, clarifying and very likely strengthening the role of catheter-based treatments in the management of acute ilio-femoral DVT.

Midterm Outcomes of Pharmacomechanical Thrombectomy in the Treatment of Lower Extremity Deep Vein Thrombosis With a Rotational Thrombectomy Device

2017 ◽  
Vol 51 (5) ◽  
pp. 301-306 ◽  
Author(s):  
Ahmet Yuksel ◽  
Oktay Tuydes
Keyword(s):  
Deep Vein Thrombosis ◽  
Lower Extremity ◽  
Postthrombotic Syndrome ◽  
Technical Success Rate ◽  
Vein Thrombosis ◽  
Rotational Thrombectomy ◽  
Thrombectomy Device ◽  
Deep Vein

Background: The purpose of this study was to assess the safety and efficacy with midterm outcomes of pharmacomechanical thrombectomy (PMT) performed by using a relatively new thrombectomy device in the treatment of lower extremity deep vein thrombosis (DVT). Methods: Between February 2014 and February 2016, a total of 46 patients with lower extremity DVT were treated with PMT by using Cleaner rotational thrombectomy system. Preprocedural, intraprocedural, postprocedural, and follow-up records of patients were collected and retrospectively analyzed. Results: Mean age of patients was 50.5 (14.8) years, and 58.7% of them were female. Technical success rate of procedure was 91.3%. Mean procedure time was 81.8 (40.3) minutes. Early clinical improvement was observed in all patients with successful treatment. No serious adverse event related to procedure and mortality was observed. Mean follow-up time was 16.0 (7.9) months. Reocclusion was observed in 7 (17.5%) patients during the follow-up period. Venous patency rates of patients at 1-, 3-, 6-, and 12-month follow-up visits were 95%, 92.5%, 89.7%, and 79.5%, respectively. Mild, moderate, and severe postthrombotic syndrome were observed in 8 (20%) patients, 4 (10%) patients, and 1 (2.5%) patient, respectively. Postthrombotic syndrome–free survival rate was 67.5%. Conclusion: Cleaner rotational thrombectomy system appears to be safe and effective in the treatment of lower extremity DVT. Further larger randomized studies are needed to determine the long-term outcomes of this treatment modality.

scholarly journals Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study

2017 ◽  
Vol 15 (5) ◽  
pp. 907-916 ◽  
Author(s):  
J.-P. Galanaud ◽  
M.-A. Sevestre ◽  
G. Pernod ◽  
C. Genty ◽  
S. Richelet ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Long Term Outcomes ◽  
Vein Thrombosis ◽  
Distal Deep Vein Thrombosis ◽  
Deep Vein

The long-term course of post-thrombotic syndrome after distal deep vein thrombosis and popliteal vein thrombosis

Flebologiia ◽  
2015 ◽  
Vol 9 (3) ◽  
pp. 21
Author(s):  
E. Yu. Soldatsky ◽  
S. M. Yumin ◽  
V. F. Agafonov ◽  
I. S. Lebedev ◽  
I. A. Zolotukhin
Keyword(s):  
Deep Vein Thrombosis ◽  
Popliteal Vein ◽  
Vein Thrombosis ◽  
Post Thrombotic Syndrome ◽  
Distal Deep Vein Thrombosis ◽  
Deep Vein

Pharmacomechanical Thrombolysis for Deep Vein Thrombosis in May-Thurner Syndrome

2017 ◽  
Vol 12 (6) ◽  
pp. 466-471
Author(s):  
Mayank Roy ◽  
Morris Sasson ◽  
Armando Rosales-Velderrain ◽  
Savannah Moon ◽  
Mark Grove ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Stent Placement ◽  
Patency Rate ◽  
Iliac Vein ◽  
Postthrombotic Syndrome ◽  
Common Iliac Vein ◽  
Vein Thrombosis ◽  
Acute Deep Vein Thrombosis ◽  
Deep Vein

Objective Patients with May-Thurner syndrome presenting with acute deep vein thrombosis benefit from early lysis of clot and endovascular treatment. We evaluated the outcome of patients with May-Thurner syndrome who presented with deep vein thrombosis, managed with pharmacomechanical thrombolysis as the primary mode of intervention, in combination with angioplasty and stent placement. Methods We reviewed all patients with May-Thurner syndrome managed in our institution between January 2009 to December 2015. Patency rate and postthrombotic syndrome were evaluated as primary end points. Results A total of seven patients (6 females, 1 male) with a mean ± SD age of 48 ± 17 years and mean ± SD body mass index of 29.64 ± 7.25 kg/m2 were identified. Six patients presented with acute deep vein thrombosis and one presented with chronic venous insufficiency. Five patients underwent pharmacomechanical thrombolysis (TRELLIS and altepase) with concomitant stenting of the common iliac vein, one had only angioplasty with stent placement, and one had only pharmacomechanical thrombolysis. Median time from presentation to pharmacomechanical thrombolysis was 4 days (range = 1–9). Patency rate and postthrombotic syndrome at 12 months were 100% and 0%, respectively. No patient experienced major bleeding or pulmonary embolism. The median length of stay was 3 days (range = 0–4). There was no mortality associated with the procedure. The mean ± SD follow-up was 26 ± 15 months. Conclusions In patients with May-Thurner syndrome, pharmacomechanical thrombolysis is an effective approach for the management of acute deep vein thrombosis, decreasing thrombus burden, and long-term postthrombotic syndrome when used in conjunction with stenting.

Sign in / Sign up

Export Citation Format

Share Document